Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have been assigned an average rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $58.55.
CRSP has been the subject of several analyst reports. BidaskClub cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 5th. Guggenheim initiated coverage on Crispr Therapeutics in a report on Tuesday, October 9th. They issued a “neutral” rating for the company. Raymond James initiated coverage on Crispr Therapeutics in a report on Thursday, September 20th. They issued an “underperform” rating for the company. Wells Fargo & Co initiated coverage on Crispr Therapeutics in a report on Wednesday, October 10th. They issued an “outperform” rating and a $65.00 target price for the company. Finally, Needham & Company LLC initiated coverage on Crispr Therapeutics in a report on Friday, November 30th. They issued a “buy” rating and a $62.00 target price for the company.
In other news, President Rodger Novak sold 17,310 shares of the stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $35.09, for a total transaction of $607,407.90. Following the completion of the transaction, the president now directly owns 1,130,697 shares in the company, valued at approximately $39,676,157.73. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Vertex Pharmaceuticals (Europe purchased 90,742 shares of the stock in a transaction dated Monday, December 24th. The shares were acquired at an average price of $24.08 per share, with a total value of $2,185,067.36. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 153,682 shares of company stock valued at $3,700,718. Company insiders own 37.70% of the company’s stock.
NASDAQ CRSP opened at $35.40 on Monday. Crispr Therapeutics has a one year low of $22.22 and a one year high of $73.90. The firm has a market capitalization of $1.84 billion, a P/E ratio of -20.70 and a beta of 3.48.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm had revenue of $0.56 million during the quarter, compared to analyst estimates of $2.64 million. During the same period in the prior year, the company posted ($0.62) earnings per share. The firm’s revenue for the quarter was down 76.6% compared to the same quarter last year. Equities analysts predict that Crispr Therapeutics will post -3.26 earnings per share for the current year.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
See Also: What is a Reverse Stock Split?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.